Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.

@article{Kost2001OpenlabelPI,
  title={Open-label phase II trial of amprenavir, abacavir, and fixed-dose zidovudine/lamivudine in newly and chronically HIV-1--infected patients.},
  author={Rhonda Kost and Arlene M Hurley and Linqi Zhang and Mika S Vesanen and Andrew Talal and Scott N Furlan and Paul J Caldwell and Judy Johnson and Lynn A Smiley and David Ho and Martin H Markowitz},
  journal={Journal of acquired immune deficiency syndromes},
  year={2001},
  volume={26 4},
  pages={332-9}
}
A Phase II clinical trial was designed to evaluate the efficacy and tolerability of twice-daily abacavir, amprenavir, and zidovudine (ZDV)/lamivudine (3TC) in HIV-1-infected study subjects naive to protease inhibitors and 3TC. Plasma and cerebrospinal fluid (CSF) HIV-1 RNA levels and T-cell subsets were measured. In all, 27 newly diagnosed and 12 chronically HIV-1-infected study subjects are included in the analysis. Week 48 plasma HIV-1 RNA levels were <500 copies/ml in 100% of study subjects… CONTINUE READING